Exelixis Shares Drop Amid Mixed Outcomes from Late-Stage Cancer Trials

Exelixis (NASDAQ: EXEL) took a hit in early trading Monday as investors reacted to a split bag of outcomes from its recent cancer studies. The biotech company revealed data from two late-stage trials testing new treatments for colorectal cancer and neuroendocrine tumors (NET), stirring the pot for the stock which fell over 9% premarket.

The colorectal cancer trial examined the combination of Exelixis' experimental drug zanzalintinib with atezolizumab (better known as Tecentriq) against regorafenib. At around the 18-month mark, patients on the combo saw a median overall survival of 10.9 months compared to 9.4 months for those on regorafenib. While there was some improvement, the data wasn't fully baked-Exelixis noted one of its dual primary endpoints remained incomplete at cutoff, although the other had been met earlier this year in June. The company plans to finish its first US new drug application for zanzalintinib in 2025, which keeps them in the game but leaves a few questions floating.

Meanwhile, the results from the neuroendocrine tumor trial - specifically the Phase 3 Cabometyx study targeting NETs of lung or thymus origin - delivered more heartening headlines. The subgroup analysis showed Cabometyx slashed the risk of disease progression or death by a hefty 81% compared to placebo. Median progression-free survival extended to 8.2 months versus just 2.7 months on placebo, painting a promising picture for this patient population.

Despite the encouraging signals from the NET trial, the mixed news on colorectal outcomes seemed to overshadow gains, sending shares tumbling. Exelixis is navigating the notoriously tough landscape of oncology treatment development where competing endpoints and drug combos can make or break momentum.

The market reaction underscores just how sensitive investors are to clinical data nuances-partial success on tough endpoints may not be enough to keep optimism afloat without clear, robust results. Investors have seen this drill before: a drug making some progress but missing ideal milestones can complicate the path forward and shake confidence.

As Exelixis eyes its 2025 drug filing deadline, the pressure's on to nail down convincing evidence of efficacy. In oncology, months feel like years, and tentative steps have a way of growing into pivotal turns for a company's fortunes.

With the biotech sector in perpetual flux, trials like these make for rough seas. Yet the promise in treating aggressive cancers keeps interest alive. Will zanzalintinib build on its mixed signals in follow-up studies? The unfolding story is one to track, even if the near-term price action says otherwise.